News | December 07, 2025
Takeda seals $1.2 billion oncology deal with Innovent Biologics
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
GV20 received an upfront payment and is eligible for additional milestone payments
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Harnessing advanced data analysis for early detection, prevention and better outcomes
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
